Phaseolin; Phaseolin (phytoalexin) | 13401-40-6

• 物质功能分类: 天然产物 - 酚类
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 异黄酮类化合物
• 英文名称: Phaseolin; Phaseolin (phytoalexin)
• 英文别名: 17,17-dimethyl-4,12,18-trioxapentacyclo[11.8.0.02,11.05,10.014,19]henicosa-1(13),5(10),6,8,14(19),15,20-heptaen-7-ol
• CAS: 13401-40-6
• 化学式: C₂₀H₁₈O₄
• 分子量: 322.4
• InChiKey: LWTDZKXXJRRKDG-UHFFFAOYSA-N

物化性质

• 熔点：
  177-178°
• 比旋光度：
  578 -145°
• 沸点：
  467.5±45.0 °C(Predicted)
• 密度：
  1.287±0.06 g/cm3(Predicted)
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  24
• 可旋转键数：
  0
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  47.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• SUCROSE TRANSPORTER GENES FOR INCREASING PLANT SEED LIPIDS
  申请人：Allen Stephen M.

  公开号：US20110126318A1

  公开（公告）日：2011-05-26

  This invention relates to polynucleotide sequences encoding SUT2 or SUT4 sucrose transporter genes. Methods for increasing seed oil content and evaluating increased oil content in a plant seed are described. The compositions and methods disclosed herein employ a variety of sequences that encode sucrose transporters and a variety of sequences that influence fatty acid accumulation, including for example, DGAT, Lec1 and ODP1 transcription factor. In specific embodiments, overexpression of SUT2 and/or SUT4 sucrose transporters in combination with DGAT genes further increase plant seed oil production compared to a high oil plant comprising recombinant DNA constructs that do not overexpress SUT2 or SUT4 transporters.

  该发明涉及编码SUT2或SUT4蔗糖转运蛋白基因的多核苷酸序列。描述了增加种子油含量和评估植物种子中增加油含量的方法。本文披露的组合物和方法采用了一系列编码蔗糖转运蛋白和影响脂肪酸积累的序列，例如DGAT、Lec1和ODP1转录因子。在具体实施方式中，过表达SUT2和/或SUT4蔗糖转运蛋白与DGAT基因结合可进一步增加植物种子的油产量，与不过表达SUT2或SUT4转运蛋白的重组DNA构建的高油植物相比。
• p-Coumaroyl-CoA:Monolignol Transferase
  申请人：Sedbrook John

  公开号：US20160046955A1

  公开（公告）日：2016-02-18

  The invention relates to nucleic acids encoding a p-coumaroyl-CoA:monolignol transferase and to inhibitory nucleic acids adapted to inhibit the expression and/or translation of a p-coumaroyl-CoA:monolignol transferase RNA. Inhibition of p-coumaroyl-CoA:monolignol transferase in plants improves the incorporation of monolignol ferulates into the lignin of plants, giving rise to plant biomass that is more easily processed into useful products such as paper and biofuels.

  该发明涉及编码p-香豆酰辅酶A：单木质素转移酶的核酸，以及适用于抑制p-香豆酰辅酶A：单木质素转移酶RNA表达和/或翻译的抑制性核酸。在植物中抑制p-香豆酰辅酶A：单木质素转移酶可改善单木质素酰基的纤维素中的结合，使得植物生物质更容易加工成纸张和生物燃料等有用产品。
• FERULOYL-CoA:MONOLIGNOL TRANSFERASE
  申请人：Wilkerson Curtis

  公开号：US20130203973A1

  公开（公告）日：2013-08-08

  The invention relates to nucleic acids encoding a feruloyl-CoA:monolignol transferase and the feruloyl-CoA:monolignol transferase enzyme that enables incorporation of monolignol ferulates, for example, including p-coumaryl ferulate, coniferyl ferulate, and sinapyl ferulate, into the lignin of plants.

  该发明涉及编码feruloyl-CoA: monolignol转移酶的核酸和feruloyl-CoA: monolignol转移酶酶，该酶使得单木素ferulates（例如p-香豆素ferulate、coniferyl ferulate和sinapyl ferulate）能够被结合到植物的木质素中。
• LIPID NANOPARTICLE MRNA VACCINES
  申请人：CureVac AG

  公开号：US20200163878A1

  公开（公告）日：2020-05-28

  The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the present invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well as an mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the use of said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination.

  该发明涉及包含脂质纳米粒子的mRNA及其医药用途。本发明的脂质纳米粒子包括根据化学式(I)、(II)或(III)的阳离子脂质和/或根据化学式(IV)的PEG脂质，以及包含编码抗原肽或蛋白质的mRNA序列的mRNA化合物。该发明还涉及将所述脂质纳米粒子用作疫苗或药物，特别是针对流感或狂犬病疫苗接种。
• NICOTINYL RIBOSIDE COMPOUNDS AND THEIR USES
  申请人：MitoPower, LLC

  公开号：US20200397807A1

  公开（公告）日：2020-12-24

  The disclosure provides nicotinamide riboside (NR), the reduced form of NR (NRH), nicotinic acid riboside (NAR), the reduced form of NAR (NARH), derivatives thereof, compositions thereof and uses thereof. The NR and NAR derivatives have improved stability and bioavailability compared to NR and NAR. NR, NRH, NAR, NARH, and derivatives thereof can increase cellular NAD + levels and enhance mitochondrial and cellular function and cell viability. Therefore, NR, NRH, NAR, NARH, and derivatives thereof, whether alone or in combination with one or more additional therapeutic agents (e.g., a mitochondrial uncoupler or/and a PARP inhibitor), are useful for treating mitochondrial diseases, mitochondria-related diseases and conditions, metabolic disorders, and other disorders and conditions.

  该披露提供烟酰胺核糖苷（NR）、烟酰胺核糖苷的还原形式（NRH）、烟酸核糖苷（NAR）、烟酸核糖苷的还原形式（NARH）、以及它们的衍生物、组合物和用途。与NR和NAR相比，NR和NAR的衍生物具有更好的稳定性和生物利用度。NR、NRH、NAR、NARH和它们的衍生物可以增加细胞NAD+水平，增强线粒体和细胞功能以及细胞存活能力。因此，NR、NRH、NAR、NARH和它们的衍生物，无论是单独使用还是与一个或多个额外治疗剂（例如线粒体解耦蛋白抑制剂和/或PARP抑制剂）结合使用，都可用于治疗线粒体疾病、与线粒体相关的疾病和症状、代谢紊乱以及其他疾病和症状。